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Efﬁcacyinfections caused by avian inﬂuenza A H7 subtype viruses underscores their
pandemic potential and the need to develop vaccines to protect humans from viruses of this subtype. A live
attenuated H7N3 virus vaccine was generated by reverse genetics using the HA and NA genes of a low
pathogenicity A/chicken/BC/CN-6/04 (H7N3) virus and the six internal protein genes of the cold-adapted A/
Ann Arbor/6/60 ca (H2N2) virus. The reassortant H7N3 BC 04 ca vaccine virus was temperature sensitive and
showed attenuation in mice and ferrets. Intranasal immunization with one dose of the vaccine protected
mice and ferrets when challenged with homologous and heterologous H7 viruses. The reassortant H7N3 BC
04 ca vaccine virus showed comparable levels of attenuation, immunogenicity and efﬁcacy in mice and ferret
models. The safety, immunogenicity, and efﬁcacy of this vaccine in mice and ferrets support the evaluation of
this vaccine in clinical trials.
Published by Elsevier Inc.Introduction
Avian inﬂuenza A H7 subtype viruses have caused large outbreaks
of disease in domestic poultry in Asia, Europe, North America, and
South America in recent years, leading to severe economic losses to the
poultry industry (Capua et al., 2002; Capua and Alexander, 2004; Hirst
et al., 2004; Jones and Swayne, 2004; Koopmans et al., 2004). Some of
these outbreaks have also been associatedwith the direct transmission
of H7 subtype viruses from infected domestic poultry to humans,
causing disease and sometimes death. Although sporadic cases of
human infections with avian inﬂuenza H7 subtype viruses had oc-
curred previously (Campbell et al., 1970; Kurtz et al., 1996; Taylor and
Turner 1977; Webster et al., 1981), H7 viruses became a greater
concern with the direct transmission of H7N7 viruses to a large num-
ber of humans in the Netherlands in 2003. A highly pathogenic (HP)
avian inﬂuenza A H7N7 subtype virus caused 89 human infections
includingone fatal case of acute respiratory distress syndromeduring a
severe disease outbreak in domestic poultry in 2003 in The Nether-
lands (Fouchier et al., 2004; Koopmans et al., 2004). InNovember 2003,
an avian inﬂuenza A H7N2 subtype virus was isolated from a patient, 33 North Drive, MSC 3203,
ao).
nc.from New York who was hospitalized for upper and lower respiratory
tract illness. The source of this virus remains unknown (http://www.
cdc.gov/mmwr/preview/mmwrhtml/mm5325a1.htm, 2004). In 2004,
two poultry workers were infected when an HP avian inﬂuenza H7N3
virus emerged in domestic poultry in British Columbia, Canada; these
infections resulted inmild respiratory disease and conjunctivitis (Hirst
et al., 2004; Pasick et al., 2005; Tweed et al., 2004). A serological survey
detected anti-H7 antibodies in 7 poultry workers who were exposed
to a low pathogenicity (LP) avian inﬂuenza H7N3 virus during avian
inﬂuenza outbreaks in Italy in 2002–2003 (Puzelli et al., 2005).
Infection of a poultryworkerwith an avian inﬂuenza AH7N3 viruswas
reported in the United Kingdom during an outbreak of avian inﬂuenza
in domestic poultry in 2006 (Nguyen-Van-Tam et al., 2006). Elevated
antibody titers against H7 subtype virus have been reported in
veterinarians in the United States who had a history of exposure to
birds (Myers et al., 2007).
This substantial number of human infections following occupational
exposure to H7 subtype viruses from avian species in recent years
underscores their pandemic potential and the need to develop efﬁ-
cacious vaccines against viruses of this subtype. A subunit vaccine based
on the HA and NA proteins of H7 viruses with immune stimulating
complexes (ISCOM) as an adjuvant induced protective immunity against
challenge infection in mice though non-adjuvanted subunit vaccines
proved to be poorly immunogenic and failed to induce protection (de
Table 1
The H7N3 BC 04 ca reassortant virus is ca and ts in PCK cells
Virus Mean virus titer±SE
(log10TCID50/ml) at
indicated temperature
caa phenotype tsb phenotype
25 °C 33 °C 39 °C
H7N3 BC 04 wt HP 5.5±0.2 9.7±0 9.7±0 − −
H7N3 BC 04 ca 8.7±0 8.7±0 6.4±0 + +
AA ca 10.7±0 10.7±0 6.2±0 + +
a ca = difference between the mean TCID50 at 33 °C and 25 °C≤100-fold.
b ts = difference between the mean TCID50 at 33 °C and 39 °C≥100-fold.
Table 2
The H7N3 BC 04 ca virus requires trypsin for efﬁcient plaque formation in CEF cells
Virus Amino acid sequence
near HA cleavage sitea
Temperature Virus titer
(log10 pfu/ml)
With
trypsin
Without
trypsin
H7N3 BC 04 wt HP PKQAY RKRMTR/GLF 37 °C 8.0 8.0
33 °C 8.2 7.8
H7N3 BC 04 ca PK———————TR/GLF 37 °C 6.2 ≤2.7b
33 °C 7.0 4.2
a / indicates site of cleavage of HA into HA1 and HA2; - indicates absence of a
corresponding residue in the aligned sequences.
b Lower limit of detection.
124 T. Joseph et al. / Virology 378 (2008) 123–132Wit et al., 2005). Two doses of a formalin inactivated H7N2-PR8 reas-
sortant virus vaccine provided protection in mice against H7 viruses
from homologous and heterologous lineages (Pappas et al., 2007).
Phylogenetic analysis of the H7 HA gene reveals a separation into
two lineages that correspond to the geographic separation of the
birds that they infect, namely Eurasian and North American lineages
(Campitelli et al., 2008). We have previously analyzed the antigenic
relatedness among H7 viruses from the two lineages using post-
infection mouse and ferret sera (Joseph et al., 2007). Based on the
phylogenetic relationships and the ability to induce broadly cross-
neutralizing antibodies in mice and ferrets, we selected the wild-type
(wt) A/chicken/BC/CN-7/04 (H7N3) (H7N3 BC 04 HPwt) virus from the
North American lineage for vaccine development (Joseph et al., 2007).
This virus was isolated during an avian inﬂuenza disease outbreak in
domestic poultry in British Columbia, Canada that resulted in human
infections in 2004. The HA protein of this virus had a 7 amino acid
insertion near the HA cleavage site (PENPKQAYRKRMTR⁎GLF) that
made the virus highly pathogenic to chickens. The source of this
peptide insertion was subsequently identiﬁed as the matrix protein
(M) of the same virus (Bowes et al., 2004; Hirst et al., 2004; Pasick et al.,
2005). The HA gene of H7N3 BC 04 HP wt virus would have to be
modiﬁed by removing the 7 amino acid peptide insertion in order to
generate a LP vaccine virus that could be safely handledunder standard
BSL-2 laboratory containment. However, the A/chicken/BC/CN-6/04
(H7N3) LP virus (H7N3 BC 04 LP wt), that was isolated from the same
outbreak did not have the 7 amino acid peptide insertion at the HA
cleavage site (PENPKTR⁎GLF), was not pathogenic to chickens and was
a precursor of the HP virus that caused severe disease in poultry.
Because the nucleotide and amino acid sequences of the HA and NA of
H7N3 BC 04 LP wt and H7N3 BC 04 HP wt viruses were identical and
the HA of H7N3 BC 04 LP wt virus did not require modiﬁcation of the
HA cleavage site, we chose the H7N3 BC 04 LPwt virus as the source of
the HA and NA genes for vaccine development.
Several strategies have been used to develop vaccines against avian
inﬂuenza viruses with pandemic potential. Inactivated virus vaccines,
live attenuated virus vaccines, vectored vaccines, andDNAvaccines have
been developed against avian inﬂuenza A H5N1 subtype viruses and
showed promise in preclinical studies (Subbarao and Joseph, 2007). Live
attenuated, cold-adapted (ca) inﬂuenza virus vaccines against human
inﬂuenza viruses elicit both systemic and mucosal immunity in the
respiratory tract (Maassab and Bryant, 1999; Murphy and Coelingh,
2002). Classical reassortment or plasmid-based reverse genetics
(Hoffmann et al., 2000) allow the generation of live attenuated ca
vaccine viruses bearing theHAandNA genes of awt virus of interest and
internal protein genes of the vaccine donor virus A/Ann Arbor/6/60 ca
(H2N2) (AA ca) that was generated by the serial passage of a wt A/Ann
Arbor/6/60 (H2N2) (AA wt) virus at successively lower temperatures
(Maassab and Bryant, 1999). Candidate live attenuated virus vaccines
against H9N2 and H5N1 avian inﬂuenza viruses generated on the AA ca
backbone using reassortment and plasmid-based reverse genetics,
respectively, were safe and efﬁcacious in mice and ferrets (Chen et al.,
2003; Li et al., 1999; Suguitan et al., 2006). Phase 1 clinical evaluation of
these vaccines is currently in progress.In this study we describe the generation of a live attenuated ca
H7N3 virus vaccine by plasmid-based reverse genetics using the HA
and NA genes of the H7N3 BC 04 LP wt virus and six internal protein
genes of the AA ca virus and demonstrate the immunogenicity and
efﬁcacy of the vaccine in mice and ferrets.
Results
Generation of the H7N3 BC 04 ca virus
A reassortant virus containing the H7 HA and N3 NA genes derived
from theH7N3BC 04 LPwt virus and remaining gene segments from the
AA ca virus was generated by plasmid-based reverse genetics as
described previously (Suguitan et al., 2006). The reassortant virus was
biologically cloned by limiting dilution in the allantoic cavity of
embryonated speciﬁc pathogen free (SPF) hen's eggs. The nucleotide
sequence of each gene segment of the reassortant virus was analyzed
and the sequence identity with the corresponding gene segment of
the parent viruses was conﬁrmed. The ﬁve mutations in the internal
protein genes, PB11195 (K391E), PB11766 (E581G), PB12005 (A661T), PB2821
(N265S), and NP146 (D34G) that specify the temperature sensitivity (ts)
and attenuation (att) phenotypes of the AA ca vaccine donor virus (Jin
et al., 2003, 2004) were present in the reassortant H7N3 BC 04 ca virus.
The H7N3 BC 04 ca virus is ts and trypsin dependent
The phenotypic properties of the H7N3 BC 04 ca and H7N3 BC 04
HP wt viruses were compared in primary chicken kidney (PCK) and
chicken embryo ﬁbroblast (CEF) cells. The H7N3 BC 04 ca and the
parent AA ca viruses replicated equally well at 25 °C and 33 °C (ca) but
not at 39 °C (ts) while the H7N3 BC 04 HP wt virus did not replicate as
efﬁciently at 25 °C as at 33 °C but replicated equally well at 33 °C and
39 °C and therefore was neither ca nor ts (Table 1).
The H7N3 BC 04 HP wt virus that possesses a 7 amino acid long
insertion at the cleavage site of the HA protein formed plaques
efﬁciently in CEF cells in the presence and absence of trypsin. TheH7N3
BC 04 ca failed to form plaques in the absence of trypsin, consistent
with the absence of a multi-basic cleavage site motif in the HA protein
(Table 2).
Attenuation of the H7N3 BC 04 ca virus in chickens, mice, and ferrets
Level of attenuation in chickens following intravenous (i.v.) and
intranasal (i.n.) inoculation
Clinical signs of illness were not observed in chickens upon i.n. and
i.v. inoculationwith the H7N3 BC 04 ca virus. The H7N3 BC 04 ca virus
was not lethal for chickens and virus was not isolated from oro-
pharyngeal or cloacal swabs that were collected on day 3 following i.n.
inoculation or from the kidney, heart, brain, and lungs of birds from the
i.n. inoculated group that were euthanized 3 days post-infection (dpi)
(data not shown). The H7N3 BC 04 ca virus also failed to elicit an
antibody response following i.n. inoculation (data not shown). The
Fig. 1. Percent change in body weight following i.n. inoculation of H7N3 viruses. Groups
of 5 mice received 106 TCID50/mouse of H7N3 BC 04 ca (□), H7N3 BC 04 wt LP (■), and
H7N3 BC 04 wt HP (▲) viruses. Mock infected mice (●) received L-15.
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be because it is a temperature sensitive virus or because the AA virus
is a human inﬂuenza virus that may be restricted in replication in
chickens.
Lethality for mice
The H7N3 BC 04wt and ca viruses were tested for lethality in mice.
Consistent with our previous ﬁndings (Joseph et al., 2007), a dose of
106 ﬁfty percent tissue culture infectious doses (TCID50) of the H7N3
BC 04 HP wt virus was lethal for mice by 7 dpi. Although the H7N3 BCFig. 2. Replication of the H7N3 BC 04 ca virus in mice. Level of replication of ca andwt viruses
bars), H7N3 BC 04wt LP (solid bars), H7N3 BC 04 ca (diagonal hatch bars), AAwt (open bars) a
(C) spleen, and (D) brain of 4mice per group sacriﬁced on 2, 3, and4 dpi, respectively are expre
limit of detection. * indicates statistically signiﬁcant (pb0.05) reduction in virus titers comp04 LP wt virus caused a slight reduction in weight by 3 dpi, all of the
mice rapidly regained weight. The H7N3 BC 04 ca virus did not cause
weight loss in mice (Fig. 1).
Replication kinetics of the H7N3 BC 04 ca virus in mice
The level of replication of the H7N3 BC 04 wt and ca viruses was
assessed in mice on 2, 3, and 4 dpi. The AA wt and AA ca viruses were
included for comparison. The H7N3 BC 04 LP and HP wt viruses
replicated to similar levels in the respiratory tract of mice (Fig. 2). The
level of replication of the H7N3 BC 04 ca virus in the upper respiratory
tract was signiﬁcantly lower than the wt viruses on 2 and 3 dpi. An
increase in the level of replication on 4 dpi suggests that peak
replication of H7N3 BC 04 ca virus may be delayed in the upper
respiratory tract as compared towt parent virus. However, replication
of the H7N3 BC 04 ca virus in the lower respiratory tract was
signiﬁcantly lower than thewt viruses on 2 and 3 dpi and it was below
the detection limit on 4 dpi. (Fig. 2). With the exception of a single
time point (day 4 in the nasal turbinates), the level of replication of the
H7N3 BC 04 ca virus was also lower than that of the attenuated AA ca
virus. The H7N3 BC 04 ca virus was undetectable in the spleen (Fig. 2).
Although low levels of wt viruses were detected in the brain, the ca
viruses were undetectable. Thus, the replication of the H7N3 BC 04 ca
virus was highly restricted in mice as compared to the wt H7N3 HP
and LP viruses.
Level of replication of the H7N3 BC 04 ca virus in ferrets
The level of replication of the H7N3 BC 04 wt and ca viruses was
evaluated in ferrets 3 days following i.n. inoculation. The AAwt and AA
ca viruses were included for comparison. While the H7N3 and AA wt
viruses and the AA ca virus replicated to high titers in the upperin mice following i.n. inoculationwith 106 TCID50/mouse of H7N3 BC 04wt HP (stippled
nd AA ca (horizontal hatch bars) viruses. Virus titers in the (A) nasal turbinates, (B) lungs,
ssed asmean±SE log10TCID50/gmof tissue. The dashed horizontal line indicates the lower
ared to the corresponding wt virus.
Fig. 3. Replication of the H7N3 BC 04 ca virus in ferrets. Level of replication of ca andwt
viruses in ferrets following i.n. inoculation with 107 TCID50/ferret of H7N3 BC 04 wt HP
(stippled bars), H7N3 BC 04 wt LP (solid bars), H7N3 BC 04 ca (diagonal hatch bars), AA
wt (open bars), and AA ca (horizontal hatch bars) viruses on 3 dpi. Virus titers are
expressed as mean±SE log10EID50/gm of tissue. The dashed horizontal line indicates the
lower limit of detection. ⁎ indicates statistically signiﬁcant (pb0.05) reduction in virus
titer compared to the H7N3 BC 04 wt viruses.
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level, between 104 and 105 ﬁfty percent egg infectious dose (EID50)/gm
(Fig. 3) and replication of the H7N3 BC 04 ca and AA ca virus were not
detected in the lower respiratory tract of ferrets. In contrast, the H7N3
BC 04wt viruses replicated to high titers in the lower respiratory tract
(Fig. 3). Moderate levels of H7N3 and AA wt viruses were detected in
the olfactory bulb. While a low level of the AA ca virus was detectable,
the H7N3 BC 04 ca viruswas not detected in the olfactory bulbs (Fig. 3).
The H7N3 BC 04 HP and LP wt viruses were detected at moderate and
low levels, respectively, but the H7N3 BC 04 ca and the AA ca viruses
were not detected in the rest of the brain (Fig. 3).
Immunogenicity of the H7N3 BC 04 ca virus
Immunogenicity in mice
The immunogenicity of the H7N3 BC 04 LP wt and H7N3 BC 04 ca
viruses was evaluated in mice following immunization with 1 or 2
doses of the immunizing virus. A single dose of H7N3 BC 04 ca induced
a detectable neutralizing antibody response against the homologousTable 3
The H7N3 BC 04 ca virus is immunogenic in mice and ferrets
Virus used for
immunization
Number of
dosesa
Geometric mean neutralizing
antibody titers achieved at indicated
time post-immunization in
indicated species
Miceb Ferretsc
D 0 D 28 D 56 D 0 D 28 D 56
H7N3 BC 04 ca 1 b10 87 403 b10 160 NDd
2 b10 45 470 b10 84 264
H7N3 BC 04 wt LP 1 b10 320 941 b10 571 ND
2 b10 154 1701 ND ND ND
a Mice and ferrets in the 1-dose group were immunized i.n. on day 0 and in the 2-
dose group were immunized on day 0 and 28 with 106 TCID50 (mice) and 107 TCID50
(ferrets) of the indicated virus.
b Geometric mean of serum neutralizing antibody titers of 3 mice against the
homologous H7N3 BC 04 wt LP virus.
c Geometric mean of serum neutralizing antibody titers of 9 ferrets that were
immunized with the H7N3 BC 04 ca virus and 3 ferrets immunized with the H7N3 BC 04
wt LP virus against the homologous H7N3 BC 04 wt LP virus.
d Not done.virus, with a geometric mean neutralizing antibody titer (GMT) of 87
by 4 weeks post-immunization (Table 3) that increased over the next
4 weeks. The ﬁnal titer achieved following two doses of vaccine was
similar to that seen 8 weeks after a single dose (Table 3). The GMT
achieved following infectionwith the H7N3 BC 04 ca virus was 2 to 4-
fold lower than the titer following infectionwith the H7N3 BC 04 LPwt
virus (Table 3).
The level of cross-neutralizing antibodies was determined in the
sera ofmice thatwere challengedwith the heterologous NL/03 (H7N7)
and EG/63 (H7N3) viruses. The GMTs against the NL/03 virus were b20
(the lowest dilution tested in this experiment) and 34 following 1 dose
of the H7N3 BC 04 ca virus at 4 and 8weeks, respectively and 60 in sera
following 2 doses of vaccine. Similarly, the GMTs against the EG/63
virus were b20 and 26 following 1 dose at 4 and 8 weeks, respectively
and 39 in sera following 2 doses of vaccine.Fig. 4. Percent change in body weight of mice i.n. immunized with a single dose of the
H7N3 BC 04 ca vaccine virus following lethal challenge with HP H7 viruses. Groups of 8
mice that were immunized with 106 TCID50 of H7N3 BC 04 ca vaccine virus (□) or were
mock-immunized (L-15) (▲) were challenged 4 weeks later with 50 LD50 of (A) H7N3 BC
04wtHP, (B) NL/03 (H7N7), and (C) EG/63 (H7N3) viruses. All immunizedmice survived
and mock-immunized mice succumbed to death between 6 and 8 dpi.
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As was seen in mice, neutralizing antibody was detectable in
ferrets 4 weeks after 1 dose of vaccine but, unlike what was seen in
mice, a higher GMT was noted following two doses of vaccine in
ferrets. We did not determine whether the antibody titer would
continue to rise in ferrets without a second dose of vaccine (Table 3).
The GMT achieved following infection with the H7N3 BC 04 ca virus
was 3 to 6-fold lower than following infectionwith the H7N3 BC 04 LP
wt virus (Table 3). The GMT against the H7N3 BC 04 HP wt virus was
similar to that against the H7N3 BC 04 LP wt virus (data not shown).
One and 2 doses of the H7N3 BC 04 ca virus induced GMTs of 11 and
10, respectively against the heterologous NL/03 (H7N7) virus in
ferrets.
Efﬁcacy of the H7N3 BC 04 ca virus in mice
Protection from lethal challenge with homologous and heterologous H7
viruses
Following immunization with 1 or 2 doses of the H7N3 BC 04
ca vaccine virus, groups of 8 mice were challenged with 50 LD50
of the H7N3 BC 04 HP wt from the North American or NL/03
(H7N7) and EG/63 (H7N3) viruses from the Eurasian lineages of H7
viruses. A single dose of the H7N3 BC 04 ca virus provided com-
plete protection from lethal challenge with all three viruses while
mock-immunized mice succumbed to death between days 6 and 8
post-challenge (data not shown). Morbidity (weight loss) following
challenge administered 4 weeks after a single dose of vaccine is
shown in Fig. 4.Fig. 5. Replication of H7wt challenge viruses in the respiratory tract of mice immunized with
2 (hatched bars) doses of 106 TCID50 of the H7N3 BC 04 ca vaccine virus or were mock-immu
indicated virus (A) 4 weeks or (B) 8 weeks post-immunization. H7N3 BC 04 wt LP and H7N3
North American lineage. EG/63 (H7N3) and NL/03 (H7N7) are antigenically heterologous HP v
of tissue from groups of 4 mice. The dashed horizontal line indicates the lower limit of detecti
to mock-immunized mice was statistically signiﬁcant (pb0.05).Protection from replication of homologous and heterologous H7
challenge viruses
The efﬁcacy of 1 or 2 doses of the H7N3 BC 04 ca virus vaccine in
preventing the replication of challenge viruses was evaluated on day 4
following challenge, when all of the challenge viruses should be
present at high titer. A single dose of the H7N3 BC 04 ca virus vaccine
(Figs. 5A and B) provided protection from pulmonary replication of
North American lineage viruses but not of Eurasian lineage viruses on
day 4 post-challenge. Two doses (Fig. 5B) of the H7N3 BC 04 ca virus
vaccine provided protection from pulmonary replication of Eurasian
lineage viruses on day 4 post-challenge.
Efﬁcacy of the H7N3 BC 04 ca vaccine virus in ferrets
Homologous H7N3 viruses from the North American lineage and a
heterologous NL/03 (H7N7) virus from the Eurasian lineage were also
used for challenge studies in ferrets following 1 or 2 doses of the
vaccine. Signiﬁcant reductions (pb0.05) in the level of challenge vi-
rus replication were observed in the upper respiratory tract (nasal
turbinates) when ferrets were challenged 4 weeks after 1 dose of the
vaccine (Fig. 6). A single dose of the vaccine provided complete
protection from the replication of the homologous H7N3 BC 04 LP wt
virus and signiﬁcantly reduced (pb0.05) the levels of replication of the
homologous H7N3 BC 04 HP wt and the heterologous NL/03 (H7N7)
viruses in the lower respiratory tract (lungs) (Fig. 6). One dose of the
vaccine also prevented the spread of NL/03 (H7N7) to the brain be-
yond the olfactory bulb and signiﬁcantly reduced (pb0.05) the virus
titers of the H7N3 BC 04 HP wt and NL/03 (H7N7) viruses in thethe H7N3 BC 04 ca vaccine virus. Groups of mice were immunized with 1 (open bars) or
nized (L-15) (solid bars) and 4 mice per group were challenged with 105 TCID50 of each
BC 04wt HP are homologous and UT/95 and VA/02 are heterologous LP viruses from the
iruses from the Eurasian lineage. Virus titers are expressed as mean±SE log10TCID50/gm
on. The reduction in virus titer in the respiratory tract of the immunizedmice compared
Fig. 6. Replication of H7wt challenge viruses in ferrets immunized with the H7N3 BC 04 ca vaccine virus. Groups of ferrets immunized with 1 (open bars) or 2 (hatched bars) doses of
107 TCID50 of H7N3 BC 04 ca vaccine virus and mock-immunized (L-15) (solid bars) ferrets were challenged 4 weeks post-dose 1 and 2 with 106 TCID50 of the indicated viruses. The
H7N3 BC 04 wt LP and H7N3 BC 04 wt HP viruses are homologous viruses from the North American lineage and NL/03 (H7N7) is a heterologous HP virus from the Eurasian lineage.
Virus titers in the nasal turbinates, olfactory bulbs, and brain are expressed asmean±SE log10TCID50/gm of tissue. Virus titers in the lungs are expressed as mean±SE log10EID50/gm of
tissue. ⁎ indicates statistically signiﬁcant (p b0.05) reduction in the virus titers. The dashed horizontal line indicates the lower limit of detection.
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virus titers in the upper respiratory tract and completely prevented
the spread of the H7N3 BC 04 HP wt and NL/03 (H7N7) viruses to the
olfactory bulb (Fig. 6). However, low levels of the homologous H7N3
BC 04 HP wt and the heterologous NL/03 (H7N7) viruses were de-
tected in the lower respiratory tract after 2 doses of the vaccine.
Discussion
Direct transmission of avian inﬂuenza A H7 subtype viruses from
infected domestic poultry to humans resulting in disease and some
times death underscores the threat posed to human health by viruses of
this subtype (Fouchier et al., 2004; Koopmans et al., 2004; Subbarao and
Joseph, 2007; Tweed et al., 2004). It is prudent to develop efﬁcacious
vaccines against H7 subtype viruses because of their pandemic po-
tential.Wehave generated a live attenuatedH7N3BC04 cavirus vaccine
by plasmid-based reverse genetics using the HA and NA genes of the
H7N3 BC 04 LPwt virus and six internal protein genes of the ca inﬂuenza
A vaccine donor strain, AA ca virus. The vaccine virus was generated
in Vero cells that are qualiﬁed for human vaccine production and
subsequent ampliﬁcation and biological cloningwere carried out in SPF
embryonatedhen's eggs. The absence ofmulti-basic amino acid residues
at the cleavage site in the HA of the H7N3 BC 04 LPwt virus thatwas the
precursor of theH7N3BC04HPwt virusobviated theneed to genetically
modify the HA gene and allowed the safe handling of the reassortant
vaccine virus under BSL-2 laboratory containment.
The H7N3 BC 04 ca vaccine virus displayed ca, ts, and att phe-
notypes that are speciﬁed by the internal protein genes of the AA ca
virus (Jin et al., 2003, 2004). Consistentwith the absence ofmulti-basic
amino acid residues at the cleavage site in the HA, the H7N3 BC 04 ca
vaccine virus was dependent on exogenous trypsin for plaque
formation in CEF cells. The H7N3 BC 04 LP wt virus and the H7N3 BC
04 ca vaccine virus were not pathogenic to chickens (Bowes et al.,
2004; Hirst et al., 2004; Pasick et al., 2005). Failure of the vaccine virus
to replicate in chickens is likely a consequence of the temperature
sensitivity of the virus or because 6 genes are derived from a humaninﬂuenza virus and suggest that the use of the H7N3 BC 04 ca vaccine
will not pose a threat to the poultry industry.
The reassortant H7N3 BC 04 ca virus was not lethal for mice.
Unlike the wt parent virus, the replication of the H7N3 BC 04 ca virus
was highly restricted in the respiratory tract of mice and systemic
(extra-pulmonary) spread was not observed. The H7N3 BC 04 ca
virus was also restricted in replication in ferrets. In ferrets, the H7N3
BC 04 ca virus replicated moderately well in the upper respiratory
tract but replication was not detected in the lower respiratory tract
and there was no spread to the brain. These characteristics of the
H7N3 BC 04 ca vaccine virus in ferrets ﬁt the attenuation criteria for
the live attenuated inﬂuenza virus vaccines (FluMist) that are
licensed for human use. The attenuation of the H7N3 BC 04 ca
vaccine virus in both mice and ferrets can be attributed to the
acquisition of the 6 internal gene segments from the AA ca virus. Live
attenuated ca H5 and H9 avian inﬂuenza A subtype virus vaccines
bearing the 6 internal protein genes of the AA ca virus have
demonstrated similar levels of attenuation in mice and ferrets (Chen
et al., 2003; Suguitan et al., 2006). Restricted replication in the
respiratory tract and lack of systemic spread in mice and ferrets
suggest that H7N3 BC 04 ca vaccine virus is sufﬁciently attenuated
for use in humans.
The H7N3 BC 04 ca vaccine virus induced neutralizing antibodieswith
comparable cross-reactivity inmice and ferrets. A single dose of theH7N3
BC 04 ca vaccine virus induced neutralizing antibodies inmice and ferrets
4 weeks post-immunization. A further rise in the antibody titer in the
mouse sera collected4weeks later is consistentwithourpreviousﬁndings
(Joseph et al., 2007). A similar phenomenon was observed in the case of
H5N1 ca vaccine viruses where antibody titers in mice continued to rise
over 8 weeks following immunization with a single dose of H5N1 ca
vaccinevirusesbut, theﬁnal titer achievedwas lower than that inducedby
2 doses of the vaccine viruses (Suguitan et al., 2006). Despite eliciting an
increase in homologous neutralizing antibody titers, two doses of the
vaccine did not increase the breadth of cross-reactivity of neutralizing
antibodies against heterologousH7 viruses from the Eurasian lineage. The
pattern of antibody response induced by the H7N3 BC 04 ca virus was
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single dose of an H9N2 ca vaccine virus induced detectable levels of
hemagglutination inhibition (HI) antibodies in ferrets and mice (Chen
et al., 2003), but the titers induced by the vaccine virus were lower than
those induced by thewtH9N2 parent virus (Chen et al., 2003). The lower
titers of HI and neutralizing antibody (Nt Ab) induced in mice and ferrets
by infectionwith the ca viruses compared to thewt parent virusesmay be
a consequence of the reduced antigen load presented by the attenuated
virus due to restricted replication. In contrast to H7N3 BC 04 ca andH9N2
ca vaccine viruses, a single dose of H5N1 ca vaccine virus was poorly
immunogenic in mice. Although anti-H5 HA ELISA antibodies were
detected in the serum, HI and virus neutralizing antibody titers were low.
A second dose of H5N1 ca vaccine elicited a signiﬁcant boost in HI and Nt
Ab response (Suguitan et al., 2006).
The efﬁcacy of the H7N3 BC 04 ca vaccine virus was demonstrated
in mice and ferrets. Viruses for the challenge studies were selected
based on our evaluation of mice infected with H7 viruses (Joseph et al.,
2007). A single dose of the vaccine completely protected mice from
lethal challenge with homologous and heterologous HP viruses from
the North American and Eurasian lineages and prevented dissemina-
tion of the challenge viruses to the brain. However, protection from
viral replication in the respiratory tract of mice following a single dose
of vaccine was only observed in mice that were challenged with
viruses from the North American lineage. Despite an increase in
homologous neutralizing antibody titers over 8 weeks following a
single dose of vaccine, the breadth of protection conferred by the
vaccine was not signiﬁcantly enhanced 4 weeks later and mice were
still not completely protected from pulmonary replication of the
challenge viruses from the Eurasian lineage. Although sera collected
following 2 doses of vaccine did not cross-neutralize heterologous
viruses from the Eurasian lineage, mice that received 2 doses of
vaccine were protected from replication of the heterologous viruses.
Thus, a statistical correlation could not be established between the
heterologous neutralizing antibody titers and level of pulmonary
replication of heterologous challenge viruses from the Eurasian
lineage in mice, suggesting that other arms of the immune system
such as mucosal antibodies or cellular immunity may contribute to
protection.
A single dose of the vaccine conferred protection from replication
of the homologous LP virus in the lower respiratory tract of ferrets. A
single dose of the vaccine also signiﬁcantly reduced the levels of
replication of homologous and heterologous HP viruses in the upper
and lower respiratory tract of ferrets and effectively prevented
dissemination of the challenge viruses to the brain and olfactory
bulb. Two doses of vaccine further reduced titers of the challenge
viruses in the upper respiratory tract but complete protection from
the replication of all challenge viruses was not observed in the lungs
despite the increase in the homologous antibody titers. In ferrets, the
number of doses of vaccine (1 or 2) and rise in the homologous
antibody titers did not affect the titers of the HP challenge viruses in
the lower respiratory tract.
We have previously evaluated the efﬁcacy of H5N1 ca and H9N2 ca
vaccine candidates in mice and ferrets. As was seen in the case of
H7N3 BC 04 ca vaccine virus, a single dose of H5N1 ca vaccines
provided complete protection from lethality following challenge with
homologous and antigenically distinct heterologous H5N1 wt viruses
(Suguitan et al., 2006). Although, a single dose of the H9N2 ca vaccine
protected mice from pulmonary replication of the homologous and
antigenically heterologous H9N2 wt challenge viruses, 2 doses of
H5N1 ca vaccines were needed to provide complete protection from
pulmonary replication of homologous and antigenically distinct
heterologous H5N1 wt viruses in mice and in ferrets (Chen et al.,
2003; Suguitan et al., 2006).
In summary, the H7N3 BC 04 ca vaccine virus was attenuated in
mice, ferrets, and chickens and was immunogenic in mice and ferrets.
The vaccine was also efﬁcacious in protecting mice and ferrets fromchallenge with homologous and antigenically distinct heterologous
H7 viruses from the Eurasian and North American lineages. Compar-
able attenuation, immunogenicity, and efﬁcacy data in mice and
ferrets support the use of the mouse model for preclinical evaluation
of vaccines against avian inﬂuenza A H7 subtype viruses. Based on the
promising preclinical data in this report, careful clinical evaluation of
the H7N3 BC 04 ca vaccine is warranted.
Material and methods
Viruses
The LP avian inﬂuenza virus H7N3 BC 04 LP wtwas used to derive
the HA and NA genes for the development of the live attenuated ca
reassortant vaccine virus H7N3 BC 04 ca. The 6 internal protein gene
segments of H7N3 BC 04 ca were derived from the ca inﬂuenza A
vaccine donor strain, AA ca (MedImmune, Mountain View, CA). The
AA wt virus that was used for this study was provided by
MedImmune. Additional viruses used for the efﬁcacy study include
HP avian inﬂuenza virus H7N3 BC 04 HP wt, LP viruses A/turkey/VA/
55/02 (VA/02) (H7N2), and A/turkey/UT/24721-10/95 (UT/95) (H7N3)
from the North American lineage and HP viruses A/Netherlands/219/
03 (NL/03) (H7N7) and A/turkey/England/63 (EG/63) (H7N3) from
the Eurasian lineage. These viruses were kindly provided by Dr.
Robert G. Webster, St. Jude Children's Research Hospital, Memphis,
TN; Dr. David Swayne, Southeast Poultry Research Laboratory, USDA,
Athens, GA; Dr. Nancy Cox, Inﬂuenza Division, Centers for Disease
Control and Prevention, Atlanta, GA; and Dr. John Pasick, Canadian
Food Inspection Agency, National Centre for Foreign Animal Disease,
Winnipeg, Canada.
The wt and reassortant ca viruses were propagated in the allantoic
cavity of 10-day-old SPF embryonated chicken eggs at 37 °C and 33 °C,
respectively, and stored at −80 °C until use. TCID50 were determined
by titration of serial 10-fold dilutions of the viruses in Madin–Darby
canine kidney (MDCK) cells and titers were determined by themethod
described by Reed and Muench (1938).
All experiments, including animal studies with LP and HP H7 avian
inﬂuenza viruses, were conducted in BSL-3+ containment laboratories
approved for use by the US Department of Agriculture and Centers
for Disease Control and Prevention. Animal experiments were ap-
proved by the National Institutes of Health Animal Care and Use
Committee.
Cloning of HA and NA expression plasmids
TheHA andNA genes of H7N3 BC 04 LPwtwere ampliﬁed by RT-PCR
using Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA) and
pfuDNA polymerase (Stratagene, La Jolla, CA). The HAvRNAwas reverse
transcribed with primer H7RT (5'-AGCAAAAGCAGGGGATACAAAATG)
and PCR ampliﬁed with primers BCH7F-Aar (5'cacttatattcacctgcctcagg-
gAGCAAAAGCAGGGG) and BCH7R-Aar (5'cctaacatatcacctgcctcgtattAG-
TAGAAACAAGGGTGTT). The NA vRNA was reverse transcribed with
BCN3RT (5'-AGCAAAAGCAGGTGCG) and PCR ampliﬁed with primers
BCN3F-Aar (5'-cacttatattcacctgcctcagggAGCAAAAGCAGGTGCG) and
BCN3R-Aar (5'-ctaacatatcacctgcctcgtattAGTAGAAACAAGGTGCTT). The
HA and NA cDNAs were cloned into the pAD3000 expression vector, a
derivative of plasmid pHW2000 (Hoffmann et al., 2000), that contains
pol I and pol II promoters but in which the bovine growth hormone
polyadenylation signal was replaced by the SV40 late mRNA poly-
adenylation sequence. Both the HA and NA primer pairs contained Aar I
restriction sites that were designed to be compatible with the BsmB I
sites present in the pAD3000 plasmid. The HA and NA plasmids
were analyzed by restriction enzyme digestion and sequence ana-
lysis. Plasmids containing viral cDNAs that were identical to the
consensus sequences of the wt vRNA were selected for virus rescue
experiments.
130 T. Joseph et al. / Virology 378 (2008) 123–132Generation of the reassortant ca virus
The reassortant ca virus was generated by plasmid-based reverse
genetics. A recombinant 6:2 reassortant that contained the HA and NA
gene segments of H7N3 BC 04 LP wt and internal protein genes of AA
cawas generated in Vero cells by electroporation using a Bio-Rad Gene
Pulser Xcell System (Bio-Rad, Hercules, CA) as previously described
(Hoffmann et al., 2000; Suguitan et al., 2006). Seed virus stocks were
generated by three rounds of cloning by limiting dilution in SPF eggs,
followed by expansion in SPF eggs. The eight gene segments of the
reassortant virus were sequenced and veriﬁed.
Evaluation of phenotypic properties of the reassortant virus
The reassortant H7N3 BC 04 ca virus was assessed for ts and ca
properties. The ts phenotype of the reassortant virus was assessed by
evaluating viral replication by cytopathic effect (CPE) in PCK cells
(Charles River Laboratories) at 33 °C (permissive) and 39 °C (non-
permissive temperature). Virus was grown in PCK cells in MEM
(Invitrogen) supplementedwith non-essential amino acids (Invitrogen),
L-glutamine (Invitrogen), and 2× concentration of antibiotic–antimyco-
tic (penicillin, streptomycin, and amphotericin B) (Invitrogen). Cells
were examined forCPE6dpi. Viruses that displayed≥100-fold reduction
in titer at 39 °C compared with that observed at 33 °C are considered ts.
The ca phenotype of the parent and reassortant viruses was
determined by comparing their infectivity in PCK cells at 25 °C and
33 °C. Cells incubated at 33 °C and 25 °C were examined for CPE at 6
and 10 dpi respectively. The ca phenotype is deﬁned as less than 100-
fold reduction of virus titer at 25 °C as compared to virus titer at 33 °C.
Plaque assay in the presence and absence of trypsin
Chicken embryo ﬁbroblast cells in 6-well tissue culture plates were
inoculated with 0.1 ml of virus serially diluted in Leibowitz (L-15)
medium. The H7N3 BC 04 HP wt and H7N3 BC 04 ca viruses were
adsorbed for 1 h, with shaking every 15 min. Wells were overlaid with
1.8% w/v Bacto agar (Difco) mixed 1:1 with 2× Medium 199 containing
antibiotics and fungizone, with or without 0.1 μg/ml porcine trypsin
(Sigma). Plates were incubated at 33 °C and 37 °C for 4–5 days. Agarose
overlays were carefully dislodged and the cell monolayers were ﬁxed
with100%methanol. Cellmonolayers in eachwellwere rinsedwith2ml
of Blotto (5% non-fat dry milk in 1× PBS) and incubated for 1 h at room
temperature with 0.5 ml/well of 1:1000 of the primary antibody in
Blotto (Chicken anti-AA ca antibody, MedImmune). Plates were washed
3 times with Blotto and incubated with 0.5 ml/well of 1:2000 of rabbit
anti-chicken Y H+L horseradish peroxidase (HRP) (Pierce, Rockford, IL)
secondary antibody in Blotto for 1 h at room temperature. Plates were
washed 3 times with PBS and plaques were stained using 0.5 ml/well of
AEC substrate solution (DAKO, Carpinteria, CA) at 37 °C for 30–45 min.
Plateswerewashedoncewithwateranddried at roomtemperature. The
number of plaques in eachwell was counted and titers were recorded in
plaque forming units (pfu) per ml.
Pathogenicity and infectivity studies in chickens
An intravenous pathogenicity test (USAHA, 1994) was used to
determine the pathogenicity of the H7N3 BC 04 ca virus for chickens.
Eight 4-week oldWhite Leghorn chickenswere inoculated i.v. with the
H7N3 BC 04 ca virus at a dose of 0.2 ml of a 1:10 dilution of stock virus
andweremonitored formortality up to 10 dpi. To determine infectivity
via a simulated natural route of exposure, a separate group of 10
chickens were inoculated i.n. with 106 TCID50 of the H7N3 BC 04 ca
virus. Oropharyngeal and cloacal swabs were collected for virus
isolation 3 dpi. Two birds from the i.n. inoculated group were
euthanized 3 dpi for virus isolation from kidney, heart, brain, and
lungs. All the remaining chickenswere euthanized and bled 14 dpi andsera were tested for evidence of seroconversion by agar gel precipitin
assay.
Pathogenicity and replication studies in mice
To assess the lethality in mice, groups of 5 four to six-week-old
female BALB/c mice (Taconic Farms, Hudson, NY) were lightly
anesthetized and infected i.n. with 106 TCID50/mouse of the H7N3 BC
04 LP wt and H7N3 BC 04 HP wt viruses and serial 10-fold dilutions
ranging from100 TCID50 to 106 TCID50/mouse of theH7N3BC 04 cavirus
in a volume of 50 µl.Miceweremonitored andweighed daily for 14 days.
To study the ability of the H7N3 BC 04 ca virus to replicate in
different tissues, groups of 12 female BALB/c mice were inoculated i.n.
with 105 TCID50 of H7N3 BC 04 HP wt, H7N3 BC 04 LP wt, H7N3 BC 04
ca, AA wt, and AA ca viruses. Four mice from each group were
euthanized on 2, 3, and 4 dpi. Nasal turbinates, lungs, brains, and
spleens were harvested, weighed, and homogenized in L-15 medium
(Invitrogen) containing 2× concentration of antibiotic–antimycotic
(penicillin, streptomycin, and amphotericin B) (Invitrogen) to make a
5% (nasal turbinates and spleen) or 10% (lungs and brain) w/v tissue
homogenate. Tissue homogenates were clariﬁed by centrifugation and
titrated in 24- and 96-well tissue culture plates containing MDCK
cells. Virus titer in each organ was determined by the method
described by Reed and Muench (1938) and expressed as log10TCID50/
gm of tissue. Log-transformed viral titers were compared using the
Mann–Whitney U test.
Replication in ferrets
Six to seven-week-old ferrets (Triple F, Sayre, PA, USA) that were
sero-negative for antibodies to currently circulating H3N2 and H1N1
human inﬂuenza viruses were used to compare the ability of wt and
ca viruses to replicate in ferret tissues. Groups of 3 ferrets were
inoculated with H7N3 BC 04 LP wt, H7N3 BC 04 ca, and AA ca viruses
and 2 ferrets were inoculated with H7N3 BC 04 HP wt and AA wt
viruses. Each ferret was inoculated i.n. with 107 TCID50 of the virus in a
volume of 0.5 ml (0.25 ml per nostril). Ferrets were monitored daily
for clinical signs of inﬂuenza and body temperatures. Ferrets were
euthanized at 3 dpi and nasal turbinates, lungs (left lower lobe), and
portions of the brain were harvested. Tissues were homogenized in L-
15 medium (Invitrogen) containing a 2× concentration of antibiotic–
antimycotic (penicillin, streptomycin, and amphotericin B) (Invitro-
gen) to make a 5% (nasal turbinates) or 10% (lung and brain) w/v tissue
homogenate. Serial 10-fold dilutions of the tissue homogenates were
prepared and 0.1 ml was inoculated into four 9–11 day-old
embryonated SPF hen's eggs. Eggs were incubated at 35 °C for 24 h
for the H7N3 BC 04 HP wt virus or 72 h for the remaining viruses.
Allantoic ﬂuid from each egg was subjected to a hemagglutination
assay using 0.5% turkey erythrocytes. Virus titers were determined as
EID50/gm of tissue using the Reed and Muench method (1938). Log-
transformed viral titers were compared using the Mann–Whitney U
test.
Evaluation of immunogenicity of the ca virus in mice and ferrets
Groups of 3 four to six-week old female BALB/cmicewere immunized
i.n. with 1 or 2 doses at a 4-week interval of 50 μl containing 106 TCID50 of
the H7N3 BC 04 LPwt or H7N3 BC 04 ca viruses. Serawere collected on 0,
28, and 56 dpi. Similarly, 7-week old ferrets that were sero-negative for
antibodies to currently circulating H3N2 and H1N1 human inﬂuenza
viruses in groups of 3 were immunized i.n. with 1 or 2 doses at a 4-week
interval of 200 μl (100 μl/nostril) containing 107 TCID50/ferret of the H7N3
BC 04 ca virus and 1 dose of the H7N3 BC 04 LP wt virus. Sera were
collected on 0, 28, and 56 dpi and 0 and 28 dpi from ferrets that were
immunized with H7N3 BC 04 ca virus and H7N3 BC 04 LP wt virus
respectively. Neutralizing antibody titers in the post-immunization sera
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microneutralization (MN) assay. Serial two-fold dilutions of heat-
inactivated serum were prepared starting from 1:10 or 1:20 dilution.
Equal volumes of serumand virus (100 TCID50)weremixed and incubated
for 60 min at room temperature. The residual infectivity of the virus-
serum mixture was determined in MDCK cells in four replicates for each
dilution. Neutralizing antibody titer was deﬁned as the reciprocal of the
highest dilutionof serumthat completelyneutralized the infectivityof 100
TCID50 of the virus as determined by the absence of CPE at day 4.
Evaluation of the efﬁcacy of the H7N3 BC 04 ca virus vaccine in mice
Protection from lethality
Groups of four to six-week old female BALB/c mice were
immunized i.n. with 1 or 2 doses at a 4-week interval with 106
TCID50 of H7N3 BC 04 ca or L-15 medium (mock-immunized). Groups
of 8 mice were challenged 4 and 8 weeks post-dose 1 and 4 weeks
post-dose 2 with 50 μl containing 50 times the 50% lethal dose (50
LD50) of the homologous H7N3 BC 04 HP wt, and heterologous NL/03
(H7N7) and EG/63 (H7N3) HP viruses (Joseph et al., 2007). Mice were
monitored and weighed daily for 14 days post-challenge.
Protection from replication of the challenge virus in mice
The levels of pulmonary replication and extra-pulmonary spread of
the challenge viruses were also evaluated. Groups of four to six-week
old female BALB/c mice were immunized i.n. with 50 μl containing 106
TCID50 of H7N3 BC 04 ca virus or L-15 medium (mock-immunized) in
1 or 2 doses 4 weeks apart. Mice were challenged 4 or 8 weeks post-
dose 1 and 4 weeks post-dose 2 with 105 TCID50 of the homologous
H7N3 BC 04 LPwt and H7N3 BC 04 HPwt viruses and the heterologous
VA/02 (H7N2) and UT/95 (H7N3) viruses from the North American
lineage and heterologous NL/03 (H7N7) and EG/63 (H7N3) viruses
from the Eurasian lineage. Nasal turbinates, lungs, and brain were
harvested at 4 days post-challenge. Tissue homogenates were
prepared as described before and titrated in MDCK cells. Virus titer
in each organ was expressed as log10TCID50/gm of tissue from groups
of 4 mice. Log-transformed viral titers were compared using the
Mann–Whitney U test.
Evaluation of the efﬁcacy of the H7N3 BC 04 ca virus vaccine in ferrets
Groups of three 7-week old ferrets that were sero-negative for
antibodies to currently circulating H3N2 and H1N1 human inﬂuenza
viruses were immunized i.n. with 1 or 2 doses at a 4-week interval
with 107 TCID50 of H7N3 BC 04 ca or L-15medium (mock-immunized),
in a volume of 200 μl/ferret (100 μl/nostril). Ferrets were challenged 4
weeks post-dose 1 and 2 with 106 TCID50 of the homologous H7N3 BC
04 LP wt and H7N3 BC 04 HP wt viruses from the North American
lineage and heterologous NL/03 (H7N7) virus from the Eurasian
lineage. Ferrets were euthanized 3 days post-challenge and nasal
turbinates, lungs (right and left lower lobes), and brainwere harvested
and homogenized. Tissue homogenates of nasal turbinates and brain
tissues were titrated in MDCK cells and virus titers were determined
and expressed as log10TCID50/gm of tissue. Because embryonated eggs
are more sensitive for detecting low concentrations of virus, lung
homogenates from the ferrets were titrated in embryonated eggs and
virus titers were expressed as EID50/gm of tissue. Log-transformed
viral titers were compared using the Mann–Whitney U test.
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